Galapagos NV (NASDAQ:GLPG) Receives Average Recommendation of “Hold” from Analysts

Galapagos NV (NASDAQ:GLPG) has been assigned a consensus recommendation of “Hold” from the five brokerages that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and one has issued a buy rating on the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $34.50.

A number of equities analysts have recently commented on the stock. StockNews.com lowered shares of Galapagos from a “buy” rating to a “hold” rating in a research report on Monday, March 18th. Bank of America reaffirmed an “underperform” rating and set a $31.00 target price (down from $41.00) on shares of Galapagos in a research report on Thursday, March 28th. Finally, Morgan Stanley reissued an “equal weight” rating and set a $38.00 price target on shares of Galapagos in a research report on Monday, April 22nd.

Hedge Funds Weigh In On Galapagos

A number of large investors have recently added to or reduced their stakes in the company. Acadian Asset Management LLC grew its holdings in Galapagos by 173.8% in the third quarter. Acadian Asset Management LLC now owns 19,149 shares of the biotechnology company’s stock worth $661,000 after purchasing an additional 12,154 shares during the last quarter. FMR LLC increased its position in Galapagos by 0.7% during the 3rd quarter. FMR LLC now owns 4,317,676 shares of the biotechnology company’s stock valued at $149,176,000 after buying an additional 28,497 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its position in Galapagos by 357.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 2,265 shares of the biotechnology company’s stock valued at $92,000 after buying an additional 1,770 shares in the last quarter. Citigroup Inc. raised its stake in Galapagos by 7,243.0% in the third quarter. Citigroup Inc. now owns 90,686 shares of the biotechnology company’s stock valued at $3,133,000 after buying an additional 89,451 shares during the last quarter. Finally, Hudson Bay Capital Management LP boosted its holdings in Galapagos by 7.7% in the third quarter. Hudson Bay Capital Management LP now owns 350,000 shares of the biotechnology company’s stock worth $12,092,000 after acquiring an additional 25,000 shares in the last quarter. 32.46% of the stock is currently owned by institutional investors.

Galapagos Trading Down 1.2 %

Shares of GLPG opened at $29.09 on Friday. The firm has a fifty day moving average price of $32.11 and a 200-day moving average price of $36.00. The firm has a market capitalization of $1.92 billion, a P/E ratio of -12.70 and a beta of 0.27. Galapagos has a 12-month low of $28.30 and a 12-month high of $45.21.

About Galapagos

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.